Karen Bae Knight, LICSW, LADC | |
23 School Street, Chester, VT 05143-0332 | |
(802) 875-1594 | |
Not Available |
Full Name | Karen Bae Knight |
---|---|
Gender | Female |
Speciality | Clinical Social Worker |
Experience | 27 Years |
Location | 23 School Street, Chester, Vermont |
Accepts Medicare Assignments | May be. She may accept the Medicare-approved amount; you may be billed for more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1285716134 | NPI | - | NPPES |
58330 | Other | VT | BLUE CROSS BLUE SHIELD |
1008031 | Medicaid | VT |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
1041C0700X | Social Worker - Clinical | 089-0000842 (Vermont) | Primary |
Mailing Address | Practice Location Address |
---|---|
Karen Bae Knight, LICSW, LADC Po Box 332, 23 School Street, Chester, VT 05143-0332 Ph: (802) 875-1594 | Karen Bae Knight, LICSW, LADC 23 School Street, Chester, VT 05143-0332 Ph: (802) 875-1594 |
News Archive
Bolstered by supportive policies and public research dollars, the United Kingdom, Israel, China, Singapore and Australia are producing unusually large shares of human embryonic stem cell research, according to a report from the Georgia Institute of Technology in the June 2008 issue Cell Stem Cell.
Antibodies that target epidermal growth factor receptor (EGFR) have proven themselves as potent anticancer drugs. Now, a team of investigators led by Shuming Nie, Ph.D., and Lily Yang, Ph.D., both at the Emory University School of Medicine and members of the Emory-Georgia Tech Nanotechnology Center for Personalized and Predictive Oncology, is aiming to capitalize on this targeting ability, using a modified anti-EGFR antibody to delivery nanoparticles into tumor cells.
A study by Dana-Farber Cancer Institute researchers offers the strongest evidence yet of the effectiveness of a novel therapy for chronic graft-versus-host disease (GVHD), a potentially life-threatening complication of donor bone marrow and stem cell transplants.
In a medical emergency, a puncture of the cranium is commonly treated with an implant. While replacements made of titanium merely plug holes, a new kind of degradable implant stimulates the body to regenerate itself: It is custom-fit and disappears to the same extent that the bone regrows.
The federal government may reimburse doctors for talking to Medicare patients and their families about "advance care planning," including living wills and end-of-life treatment options -; potentially rekindling one of the fiercest storms in the Affordable Care Act debate.
› Verified 8 days ago